Program
Platinum Compounds
Also written as “QLS5132; Platinum; Bevacizumab”, “HS-10502 + Platinum + Bevacizumab” and “Platinum”.
Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Head and Neck Neoplasms, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 10 open or running | phase 1since Jun 24, 2016 | Jun 24, 2016 | none ahead |
| Eli Lilly | 10 open or running | phase 2since Jun 1, 2005 | Jun 1, 2005 | none ahead |
| Hansoh Pharmaceutical Group | 11 open or running | phase 1since Jan 7, 2025 | Jan 7, 2025 | none ahead |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 3since Jul 19, 2005 | Jul 19, 2005 | none ahead |
| Qilu Pharmaceutical | 11 open or running | phase 2since Mar 1, 2026 | Mar 1, 2026 | Apr 2027phase 2 · NCT07453394 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 1, 2005First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Eli LillyEli Lilly · NCT00112346 · 120 enrolled · United States, Canada
- Jul 19, 2005Merck KGaA, Darmstadt, Germany's first study: phase 3 study in Head and Neck NeoplasmsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT00122460 · 442 enrolled · Austria, Belgium, Czech Republic and more
- Jun 24, 2016Bristol-Myers Squibb's first study: phase 1 study in Small Cell Lung CarcinomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02815592 · 12 enrolled · Spain
- Jan 7, 2025Hansoh Pharmaceutical Group's first study: phase 1 study in Ovarian NeoplasmsNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT06769425 · 157 planned · China
- Mar 1, 2026Qilu Pharmaceutical's first study: phase 2 study in Stomach NeoplasmsNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07453394 · 626 planned
Ahead
- Apr 2027Primary completion: phase 2 study in Stomach NeoplasmsQilu Pharmaceutical · NCT07453394
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07453394Stomach Neoplasms | 2 | Not yet recruiting | Qilu Pharmaceutical | Apr 2027 | 626 |
| NCT06769425Ovarian Neoplasms · China | 1 | Recruiting | Hansoh Pharmaceutical Group | May 7, 2026 | 157 |
| NCT02815592Small Cell Lung Carcinoma · Spain | 1 | Completed | Bristol-Myers Squibb | Dec 15, 2019 | 12 |
| NCT00122460Head and Neck Neoplasms · Austria, Belgium, Czech Republic and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Mar 2007 | 442 |
| NCT00112346Carcinoma, Non-Small-Cell Lung · United States, Canada | 2 | Completed | Eli Lilly | Dec 2006 | 120 |
How it is read
Names in the registry
- “QLS5132; Platinum; Bevacizumab”, 1 entry
- “HS-10502 + Platinum + Bevacizumab”, 1 entry
- “Platinum”, 1 entry
- “Cetuximab + platinum + gemcitabine”, 1 entry
- “Platinum + Gemcitabine”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 1 study
- Ovarian Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Head and Neck Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.